Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pancreas

• Publication date

  1999-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00006676-199911000-00008PMID 10547197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of matrix metalloproteinase activity in human pancreatic cancer

  2004cited by this paper
• Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer.

  1999cited by this paper
• Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.

  1998cited by this paper
• Involvement of matrix metalloproteinase‐2 activity in invasion and metastasis of pancreatic carcinoma

  1998cited by this paper
• Presence of Two Signaling TGF-β Receptors in Human Pancreatic Cancer Correlates with Advanced Tumor Stage

  1997cited by this paper
• Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

  1997cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• MAD‐related Genes on 18q21.1, Smad2 and Smad4, Are Altered Infrequently in Esophageal Squamous Cell Carcinoma

  1997cited by this paper
• Stromal Expression of MMP‐9 and Urokinase Receptor Is Inversely Associated with Liver Metastasis and with Infiltrating Growth in Human Colorectal Cancer: A Novel Approach from Immune/Inflammatory Aspect

  1997cited by this paper
• Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

  1997cited by this paper
• Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes.

  1997cited by this paper
• Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression

  1997cited by this paper
• Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas

  1997cited by this paper
• Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.

  1997cited by this paper
• Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

  1997cited by this paper
• Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia.

  1997cited by this paper
• Inactivation of Smad4 in gastric carcinomas.

  1997cited by this paper
• Adjuvant chemotherapy in pancreatic cancer

  1997cited by this paper
• TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

  1997cited by this paper
• Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.

  1997cited by this paper
• Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system.

  1996cited by this paper
• Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.

  1996cited by this paper
• Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells*

  1996cited by this paper
• Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.

  1996cited by this paper
• Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.

  1996cited by this paper
• Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture.

  1996cited by this paper
• Identification of Important Regions in the Cytoplasmic Juxtamembrane Domain of Type I Receptor That Separate Signaling Pathways of Transforming Growth Factor-β (*)

  1996cited by this paper
• TYPE‐1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA

  1996cited by this paper
• Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations.

  1996cited by this paper
• Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition

  1996cited by this paper
• DPC4 gene in various tumor types.

  1996cited by this paper
• Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast.

  1996cited by this paper
• Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

  1996cited by this paper
• Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

  1995cited by this paper
• Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism.

  1995cited by this paper
• Mechanism of activation of the TGF-beta receptor.

  1994cited by this paper
• K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

  1994cited by this paper
• Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival.

  1993cited by this paper
• Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression.

  1993cited by this paper
• Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities.

  1993cited by this paper
• Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.

  1993cited by this paper
• Pancreatic carcinoma.

  1992cited by this paper
• Transforming growth factor-beta: recent progress and new challenges

  1992cited by this paper
• Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

  1992cited by this paper
• Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro.

  1992cited by this paper
• The transforming growth factor-beta family.

  1990cited by this paper

• Crosstalk of TGF-β and somatostatin signaling in adenocarcinoma and neuroendocrine tumors of the pancreas: a brief review

  2025cites this paper
• Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies patient subgroups with adverse outcome

  2025cites this paper
• TGF-β signaling in health, disease and therapeutics

  2024cites this paper
• Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.

  2023cites this paper
• SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4

  2022cites this paper
• Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer

  2022cites this paper
• An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer

  2022cites this paper
• Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches

  2021cites this paper
• Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor

  2021cites this paper
• SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• The Role of Glypican-1 in the Tumour Microenvironment.

  2020cites this paper
• Tumor Microenvironment: Extracellular Matrix Components – Part A

  2020cites this paper
• Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer

  2020cites this paper
• TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma

  2019cites this paper
• Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer

  2019cites this paper
• Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease

  2019cites this paper
• Blocking CXCLs–CXCR2 axis in tumor–stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment

  2019cites this paper
• Contextual determinants of TGFβ action in development, immunity and cancer

  2018cites this paper
• TGF-β in pancreatic cancer initiation and progression: two sides of the same coin

  2017cites this paper
• TGF-β Tumor Suppression through a Lethal EMT.

  2016cites this paper
• Targeting pancreatic cancer stem cells

  2016cites this paper
• Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer.

  2016cites this paper
• Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5

  2016cites this paper
• Super-resolution imaging and tracking of TGF-β receptor II on living cells

  2016cites this paper
• Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer.

  2015cites this paper
• Hexon Modification to Improve the Activity of Oncolytic Adenovirus Vectors against Neoplastic and Stromal Cells in Pancreatic Cancer

  2015cites this paper
• Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

  2015cites this paper
• LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.

  2015influential citation
• LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells.

  2015cites this paper
• LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells.

  2015cites this paper
• An Exploration into the Molecular Recognition of Signal Transducer and Activator of Transcription 3 Protein Using Rationally Designed Small Molecule Binders

  2014cites this paper
• Targeting Clinically Viable Protein-Protein Interactions via Rationally Designed Small Molecule Inhibitors

  2014cites this paper
• Pancreatic cancer: systemic combination therapies for a heterogeneous disease.

  2014cites this paper
• Einfluss des Keratinozyten-Wachstumsfaktors Palifermin auf Mukositiden nach hämatopoetischer Stammzelltransplantation

  2013cites this paper
• Towards a tailored therapy in pancreatic cancer.

  2013cites this paper
• Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

  2013cites this paper
• Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma

  2013cites this paper
• Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

  2012cites this paper
• A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells

  2011cites this paper
• Treatment of Pancreatic Cancer: What Can We Really Predict Today?

  2011cites this paper
• Discovery and Optimization of Novel Small-molecular Inhibitors Suppressing Stat3-dependent Tumor Process

  2011cites this paper
• IκB Kinase ε expression in pancreatic ductal adenocarcinoma.

  2011cites this paper
• Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.

  2011cites this paper
• Signaling pathways in pancreatic cancer.

  2011cites this paper
• Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

  2011cites this paper
• Inhibiting Cxcr 2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

  2011cites this paper
• Emerging pathways and future targets for the molecular therapy of pancreatic cancer

  2011cites this paper
• A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.

  2010cites this paper
• Significance of phospho‐vascular endothelial growth factor receptor‐2 expression in pancreatic cancer

  2010cites this paper
• 17 Smad4/TGF-b Signaling Pathways in Pancreatic Cancer Pathogenesis

  2010cites this paper
• Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer.

  2010cites this paper
• 54 Emerging Therapeutic Targets for Pancreatic Cancer

  2010cites this paper
• Molecular biology, models, and histopathology of chronic pancreatitis and pancreatic cancer

  2009cites this paper
• TGFBR 1 Haplotypes and Risk of Non – Small-Cell Lung Cancer

  2009cites this paper
• TGFBR1 haplotypes and risk of non-small-cell lung cancer.

  2009cites this paper
• High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients

  2009cites this paper
• Pancreatic Cancer: Translational Implications

  2009cites this paper
• LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

  2008cites this paper
• Aberrant Transforming Growth Factor-β Signaling in Human Pancreatic Cancer: Translational Implications

  2008cites this paper
• Rationale for Anti-TGF-β Antibody Therapy in Oncology

  2008cites this paper
• Transforming Growth Factor-β (TGF-β) Signaling Inhibitors in Cancer Therapy

  2008cites this paper
• Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.

  2007cites this paper
• Molecular prognostic factors in patients with pancreatic cancer

  2007cites this paper
• Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

  2007cites this paper
• Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

  2007cites this paper
• Stromal biology of pancreatic cancer

  2007cites this paper
• Inhibition of Transforming Growth Factor-β Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy

  2006cites this paper
• Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.

  2006cites this paper
• Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.

  2006cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma.

  2006cites this paper
• FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth

  2006cites this paper
• Inhibition of TGFbeta signaling in cancer therapy.

  2006cites this paper
• Inhibition of TGFβ signaling in cancer therapy

  2006cites this paper
• Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

  2006cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2006cites this paper
• Molecular prognostic markers in pancreatic cancer: a systematic review.

  2005cites this paper
• Histological and Molecular Markers for Pancreatic Adenocarcinoma: Can They Help Us Define Which Patients Should Receive It?

  2005cites this paper
• Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients

  2004cites this paper
• Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer

  2004cites this paper
• Overexpressed Decorin in Pancreatic Cancer

  2004cites this paper
• Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells.

  2004cites this paper
• Pancreatic tumor cells influence the composition of the extracellular matrix.

  2004cites this paper
• TGF-β and p53 Staining in CT-Guided and Endoscopic Ultrasound Fine-Needle Aspirates of Pancreatic Adenocarcinoma

  2004cites this paper
• Pathways for aberrant angiogenesis in pancreatic cancer

  2003cites this paper
• Targeting the TGFβ signaling network in human neoplasia

  2003cites this paper
• Targeting the TGF beta signaling network in human neoplasia.

  2003cites this paper
• Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer

  2003cites this paper
• Coexpression of IGF-1R and c-Src Proteins in Human Pancreatic Ductal Adenocarcinoma

  2003cites this paper
• Induction and expression of betaig-h3 in pancreatic cancer cells.

  2002cites this paper
• Induction and expression of βig-h3 in pancreatic cancer cells

  2002cites this paper
• Identification of the Prelinitis Condition in Gastric Cancer and Analysis of TGF-β, TGF-β RII and pS2 Expression

  2002cites this paper
• TGFβ-regulated transcriptional mechanisms in cancer

  2002cites this paper
• TGFβ-mediated signaling and transcriptional regulation in pancreatic development and cancer

  2001cites this paper
• TGFbeta-mediated signaling and transcriptional regulation in pancreatic development and cancer.

  2001cites this paper
• Identification of the prelinitis condition in gastric cancer and analysis of TGF-beta, TGF-beta RII and pS2 expression.

  2001cites this paper
• The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.

  2001cites this paper
• The transforming growth factor-beta signaling pathway in tumorigenesis.

  2001cites this paper
• Signaling pathways in pancreatic cancer.

  2001cites this paper
• The transforming growth factor-β signaling pathway in tumorigenesis

  2001cites this paper
• Matrix metalloproteinases (MMPs) and pancreatic diseases

  2001cites this paper